Administration of chymase inhibitors to animal models of atherosclerosis, hypertension and heart failure demonstrated multiple beneficial effects including reduced atherosclerotic plaque development [39], improved LV contractility [40] and attenuated post-MI cardiac remodeling with overall improved survival [4]. Here, CMA1 is linked to heart failure.